While the the B.1.351 variant has yet to break 1%, there are two other variants currently on the rise in the US, with the important caveat that they are only on the rise in a relative sense. That is, covid

Here's a report of the Novavax trial in South Africa. They found 60% efficacy 7 days after the second shot for HIV-negative people. This was in a background of almost all B.1.351 variant. This variant